Tumor necrosis factor-α-based gene therapy enhances radiation cytotoxicity in human prostate cancer

Cancer Gene Therapy

Volumn 5, Issue 6, 1998, Pages 344-349

  Chung, Theodore D K ^a,c   Mauceri, Helena J ^a   Hallahan, Dennis E ^a   Yu, Jianqing J ^a   Chung, Sumi ^a   Grdina, Wendy L ^a   Yajnik, Santosh ^a   Kufe, Donald W ^b   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Genetic radiotherapy; Prostate cancer; Radiation; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE THERAPY; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032199393     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hanks GE. External beam radiation treatment for prostate cancer: still the gold standard. Oncology. 1992;6:79-86.
2. Bagshaw MA, Kaplan ID, Cox RC. Radiation therapy for localized disease. Cancer. 1993;71:939-952.
3. Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV, Owen JB. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure, Int J Radiat Oncol Biol Phys. 1993;28: 39-45.
4. Perez CA, Hanks GE, Leibel SA, Zeitman AL, Fuks Z, Lee WR. Localized carcinoma of the prostate (stages T1B, T1C, T2 and T3): review of management with external beam radiation therapy. Cancer. 1993;72:3156-3161.
5. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988;115:1299-1303.
6. Perez CA, Pilepich MV, Zivnuska F. Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1986;2:523-527.
7. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley W, Grignon D, Caplan R, Cox JD. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radia-tion therapy oncology group. Int J Radiat Oncol Biol Phys. 1995;45:616-623.
8. Weichselbaum RR, Hallahan DE, Sukhatme VP, Kufe DW. Gene therapy targeted by ionizing radiation. Int J Radiat Oncol Biol Phys. 1992;24:565-567.
9. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, Kufe DW. Radiation targeting of gene therapy preferentially radiosensitizes tumor cells. Cancer Res. 1994;54:4266-4269.
10. Weichselbaum RR, Wayne JD, Mauceri HJ, Seung LP, Hanna NN, Kharbanda S, Hallahan DE, Kufe DW. Ionizing radiation: a molecular switch for gene therapy. In: Sobol RE, Scanlon KJ, eds. The Internet Book of Gene Therapy. Stamford, Connecticut: Appleton & Lange; 1995: 205-210.
11. Khil MS, Kim JH, Mullen CA, Kim SH, Freytag SO. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res. 1996;2:53-57.
12. Buchsbaum DJ, Raben D, Stackhouse MA, Khazaeli MB, Rogers BE, Rosenfeld ME, Liu T, Curiel DT. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Ther. 1996;3:1042-1068.
13. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy by ionizing radiation. Nat Med. 1995;1:786-791.
14. Leith JT, Quaranto L, Padfield G, Michelson S, Hercbergs A. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int J Radiat Oncol Biol Phys. 1993;25:283-287.
15. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig Urol. 1979;17:16-23.
16. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into adenovirus type 5. Virology. 1988;173:614-617.
17. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate. 1988;12:99-103.
18. Hallahan DE, Beckett MA, Kufe D, Weichselbaum RR. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines, Int J Radiat Oncol Biol Phys. 1990;19:69-74.
19. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
20. Sugarman BJ, Agganval BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human tumor necrosis factor-á: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943-945.
21. Sherwood ER, Ford TR, Lee C, Kozlowski JM. Therapeutic efficacy of recombinant tumor necrosis factor α in an experimental model of human prostatic carcinoma. J Biol Response Modif. 1990;9:44-48.
22. Liu S, Ewing MW, Anglard P, Trahan E, La Rocca RV, Myers CE, Linehan WM. The effect of suramin, tumor necrosis factor and interferon-γ on human prostate carcinoma. J Urol. 1991;145:389-394.
23. Fruehauf JP, Myers CE, Sinha BK. Synergistic activity of suramin with tumor necrosis factor a and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst. 1990;82:1206-1209.
24. Dewey WC. In vitro systems: standardization of endpoints. Int J Radiat Oncol Biol Phys. 1979;5:1165-1174.
25. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor α mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA. 1989;86:10104-10107.
26. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996; 56:4311-4314.
27. Sersa G, Willingham V, Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer. 1988;42:129-134.
28. Kooistra A, van den Eijnden-van Raaij AJ, Klaij IA, Romijn JC, Schroder FH. Stromal inhibition of prostatic epithelial cell proliferation not mediated by transforming growth factor beta. Br J Cancer. 1995;72:427-434.